[{"address1": "Building 7", "address2": "Kiryat Atidim", "city": "Tel Aviv", "zip": "6158002", "country": "Israel", "phone": "972 77 331 0156", "website": "https://www.chemomab.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Adi Mor George Ph.D.", "age": 41, "title": "Co-Founder, Chief Scientific Officer, CEO & Executive Director", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 330000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sigal  Fattal CPA, M.B.A.", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 322000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew B. Frankel M.B.A., M.D.", "age": 54, "title": "Chief Medical Officer & VP of Drug Development", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 850000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Barbara  Lindheim", "title": "Consulting Vice President of Investor & Public Relations, Strategic Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jack  Lawler", "title": "Senior VP of Global Clinical Development Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.42, "open": 2.42, "dayLow": 2.185, "dayHigh": 2.43, "regularMarketPreviousClose": 2.42, "regularMarketOpen": 2.42, "regularMarketDayLow": 2.185, "regularMarketDayHigh": 2.43, "beta": 0.313, "forwardPE": -57.25, "volume": 316139, "regularMarketVolume": 316139, "averageVolume": 208970, "averageVolume10days": 567350, "averageDailyVolume10Day": 567350, "bid": 2.26, "ask": 2.3, "bidSize": 300, "askSize": 200, "marketCap": 32882568, "fiftyTwoWeekLow": 0.42, "fiftyTwoWeekHigh": 2.55, "fiftyDayAverage": 1.22608, "twoHundredDayAverage": 0.83353, "currency": "USD", "enterpriseValue": 682617792, "floatShares": 166641272, "sharesOutstanding": 14359200, "sharesShort": 19475, "sharesShortPriorMonth": 105014, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0014, "heldPercentInsiders": 0.11566, "heldPercentInstitutions": 0.25069, "shortRatio": 0.09, "shortPercentOfFloat": 0.0014, "bookValue": 0.695, "priceToBook": 3.294964, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -14997000, "trailingEps": -1.06, "forwardEps": -0.04, "lastSplitFactor": "1:16", "lastSplitDate": 1615939200, "enterpriseToEbitda": -42.746, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CMMB", "underlyingSymbol": "CMMB", "shortName": "Chemomab Therapeutics Ltd.", "longName": "Chemomab Therapeutics Ltd.", "firstTradeDateEpochUtc": 1549981800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f2fd6842-2d35-37be-bf48-b334c1a2bb54", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.29, "targetHighPrice": 13.0, "targetLowPrice": 4.0, "targetMeanPrice": 8.67, "targetMedianPrice": 9.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 12727000, "totalCashPerShare": 0.044, "ebitda": -15969000, "totalDebt": 360000, "quickRatio": 3.106, "currentRatio": 3.123, "debtToEquity": 3.605, "returnOnAssets": -0.4618, "returnOnEquity": -0.93802, "freeCashflow": -11364375, "operatingCashflow": -16130000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]